Why is the antibody screen performed before transfusion?

The screen identifies clinically significant red cell alloantibodies that would destroy transfused cells, allowing the blood bank to select antigen-negative units and prevent acute or delayed haemolytic transfusion reactions.

What does a positive antibody screen mean in pregnancy?

A positive screen in pregnancy indicates maternal red cell alloantibodies that may cross the placenta and cause haemolytic disease of the foetus and newborn. It prompts antibody identification, paternal antigen typing, serial titres, and foetal surveillance.

Is fasting required for an antibody screen?

No. The antibody screen does not require fasting and can be drawn at any time, though it is often combined with other prenatal or pre-operative tests.

How long do antibody screen results take?

Negative screens are typically reported within one to two business days. Positive screens trigger antibody identification panels and may take two to four days. Urgent transfusion requests can be expedited with communication to the blood bank.

Can a negative antibody screen miss some antibodies?

Yes. Very-low-titre or newly forming antibodies may fall below detection, and antibodies to low-incidence antigens are not covered by standard reagent panels. A negative result does not exclude all possible alloantibodies or rule out historical sensitisation that may reappear on re-exposure.

What happens if my antibody screen is positive?

A positive screen triggers reflex antibody identification by the blood bank to determine the specificity and clinical significance of the antibody. The clinical team receives a report with transfusion recommendations (antigen-negative blood) or obstetric management guidance (titre monitoring, foetal assessment).

Does recent transfusion or IVIG affect the antibody screen?

Yes. Recent transfusion can introduce donor red cells or passive antibodies that confound the screen and identification. Intravenous immunoglobulin can produce a positive direct antiglobulin test. Document the timing of transfusion or IVIG on the request form.

BML-INF-080infectious diseaseUSA

Antibody Screen

The Antibody Screen detects red blood cell alloantibodies in patient serum using the indirect antiglobulin test, identifying antibodies capable of causing haemolytic transfusion reactions or haemolytic disease of the foetus and newborn. It is central to pre-transfusion compatibility testing and prenatal screening, with positive results requiring full antibody identification and antigen-negative…

Biomarkers

Blood (whole blood)

Sample

1–2 business days for negative screens; 2–4 days if positive and antibody identification is required

Turnaround

Fasting

What is the Antibody Screen test?

The Antibody Screen detects and characterises red blood cell alloantibodies in patient serum, using an indirect antiglobulin technique that reveals antibodies capable of binding foreign red cell antigens. It is ordered to ensure safe transfusion, to identify women at risk of haemolytic disease of the foetus and newborn, and to investigate unexplained haemolysis or transfusion reactions. The screen sits at the crossroads of transfusion medicine and obstetrics. In transfusion, it is one half of the 'type and screen': ABO and RhD typing plus the antibody screen together allow blood banks to hold compatible units or to issue O-negative blood in an emergency. In pregnancy, the screen is performed at booking and again in the third trimester to detect maternal antibodies that may cross the placenta and destroy foetal red cells. Practitioners order the test not for diagnosis of infection — despite the assay's name and this page's taxonomic home — but to characterise immune sensitisation and guide product selection or obstetric management.

What does the Antibody Screen test measure?

RBC Ab(Red Blood Cell Alloantibodies)

Range: Negative for clinically significant antibodies.Optimal: Negative. Any positive screen warrants full antibody identification and clinical correlation.Qualitative (positive/negative) / Semi-quantitative titre

Red blood cell alloantibodies are immunoglobulins — predominantly IgG, though IgM antibodies also occur — formed when the immune system encounters foreign red cell antigens through transfusion, pregnancy, or rarely transplantation. The initial antibody screen uses the indirect antiglobulin test: patient serum is incubated with reagent red cells of known antigen phenotype, and after washing, anti-human-globulin reagent detects bound IgG or complement. A positive screen triggers antibody identification panels to determine specificity. Clinically significant antibodies are those capable of shortening red cell survival in vivo — Rh (D, C, E, c, e), Kell, Duffy, Kidd, and S/s being the most frequent — while others such as Lewis or P₁ rarely cause haemolysis.

The antibody screen is the cornerstone of pre-transfusion and prenatal immunohaematology. A positive result requires identification of the antibody and selection of antigen-negative blood for transfusion, preventing acute or delayed haemolytic reactions. In pregnancy a positive screen identifies women at risk of haemolytic disease of the foetus and newborn, prompting paternal antigen typing, serial maternal antibody titres, and foetal surveillance. The screen is also performed before procedures with a moderate or high likelihood of transfusion, and serially in patients with alloantibodies to detect new specificities or rising titres.

Why is the Antibody Screen test ordered?

Pre-transfusion screening of all patients before elective or emergency blood component therapy, as part of compatibility testing
First-trimester prenatal screening to identify women at risk of haemolytic disease of the foetus and newborn, with repeat testing around 28 weeks' gestation
Investigation of suspected acute or delayed haemolytic transfusion reaction, where a newly positive or strengthening antibody may explain haemolysis
Pre-operative assessment of patients scheduled for procedures with moderate or high likelihood of transfusion (cardiothoracic, orthopaedic, vascular, or transplant surgery)
Serial monitoring of known alloantibody titres in pregnant women to guide timing of foetal surveillance and delivery
Work-up of unexplained anaemia or haemolysis when immune destruction of red cells is considered, alongside direct antiglobulin testing
Evaluation of haematopoietic stem cell or solid organ transplant candidates and recipients, where passenger lymphocyte syndrome or ABO incompatibility may produce alloantibodies

Sample collection and turnaround

Sample type

Blood (whole blood)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

1–2 business days for negative screens; 2–4 days if positive and antibody identification is required

Collection notes

Phlebotomy at the processing laboratory's draw site (LabCorp or Access Medical Laboratories, depending on routing). Whole blood collected in EDTA (lavender-top) or clot tubes, depending on laboratory protocol; serum or plasma is separated for testing. Document recent transfusion or IVIG, which can confound interpretation.

Specimen requirements

Minimum 5–7 mL whole blood (EDTA or serum separator tube, per laboratory protocol). Separate serum or plasma promptly and refrigerate if not tested immediately. Note any recent transfusion, pregnancy, or transplant history on the request form.

What can affect Antibody Screen results?

variableRecent blood transfusion or intravenous immunoglobulin

Transfused donor red cells or passive antibodies in IVIG can produce a positive direct antiglobulin test or confound antibody identification; the temporal relationship to transfusion must be documented.

reducesImmunosuppressive therapy and hypogammaglobulinaemia

Patients on intensive immunosuppression or with severe antibody deficiency may have weakened or undetectable antibody responses, so a negative screen does not exclude prior sensitisation.

variableCold autoantibodies and high-titre, low-avidity antibodies

Cold agglutinins can interfere with the antiglobulin phase or mask underlying alloantibodies; warm autoantibodies require adsorption techniques to reveal coexisting alloantibodies.

reducesSpecimen age and storage temperature

Antibody activity declines if serum or plasma is not separated promptly or is stored at room temperature for prolonged periods; refrigerated specimens retain activity for several days.

elevatesPregnancy and recent delivery

Foetomaternal haemorrhage during pregnancy or delivery can boost pre-existing antibody titres or induce new alloantibodies, so post-partum screens may be transiently more positive.

variablePrevious pregnancy or transfusion remote in time

Antibody titres can wane below detection years after sensitisation and reappear (anamnestic response) upon re-exposure, so a negative screen does not guarantee the absence of historical sensitisation.

What do Antibody Screen results mean?

Elevated

Not applicable; the antibody screen is qualitative (positive or negative) and, if positive, semi-quantitative titres are reported. A positive result indicates the presence of one or more red cell alloantibodies and mandates full antibody identification to determine specificity and clinical significance.

Normal

Negative. No clinically significant red cell alloantibodies detected. ABO- and RhD-compatible blood may be issued, and in pregnancy no increased risk of haemolytic disease is identified at the time of testing. A repeat screen is standard in the third trimester and before any transfusion if the prior screen is more than a few days old.

Reduced

Not applicable.

Note: A negative screen does not exclude all red cell antibodies — very-low-titre or newly forming antibodies may be missed, and antibodies to low-incidence antigens are not detected by standard panels. Positive screens require identification panels run by the blood bank; the clinical team receives the antibody specificity, clinical significance, and any special transfusion requirements. Direct antiglobulin testing (DAT) detects antibody already bound to the patient's own red cells and is a separate, complementary test.

Frequently asked questions

The antibody screen (indirect antiglobulin test) detects free antibodies in the patient's serum or plasma that may react with transfused red cells. The direct antiglobulin test detects antibody already coating the patient's own red cells. Both are complementary in investigating haemolysis.

How to access the Antibody Screen test

The Antibody Screen reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

Fung MK, et al. (eds). AABB Technical Manual, 20th edition. American Association of Blood Banks. (2020)
Royal College of Obstetricians and Gynaecologists. The use of anti-D immunoglobulin for rhesus D prophylaxis (Green-top Guideline No. 22). (2021)
Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. (2008)
Delaney M, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. (2016)
National Institute for Health and Care Excellence. Blood transfusion (NICE guideline NG24). (2015)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.